About Chronic Kidney Disease
Twenty-six million American adults have Chronic Kidney Disease (“CKD”) and millions of others are at increased risk. CKD is a progressive disease which ultimately leads to kidney failure. There are more than half a million patients whose kidneys have failed, requiring them to seek treatment. Of these patients, approximately 370,000 are receiving hemodialysis and this number is growing year on year. In 2011, the total medical care costs for Chronic Renal Failure reached an estimated $49.2 billion. On-line HDF represents an alternative treatment option for chronic renal failure with potential advantages over standard hemodialysis. On-line HDF is practiced in certain countries outside the U.S.; however, the Nephros HDF system is the only FDA cleared device currently available in the U.S.
Renal Research Institute (RRI) was established in 1997 as a research division of Fresenius Medical Care AG & Co. KGaA. It is an administratively distinct institution which collaborates with a select group of US based dialysis facilities with strong ties to academic research centers. RRI trains research fellows from countries around the world in kidney disease-related clinical research. Its research spans a full spectrum of interests from molecular biology, clinical research, and pharmaceutical trials to epidemiology. The network of international collaborators has made it a global research institution with ties to Europe, Asia, Central and South America and Africa. RRI's primary goal is to produce measurable improvements in patient outcomes by building on a solid foundation of clinical research in nephrology. RRI evaluates the development and application of new technology to enhance the quality of patient care.